Occupier

Find Out The Latest

Welcome to the latest news from The Oxford Science Park, where you can keep up to date with developments across our community. From company milestones and scientific breakthroughs to investment news, partnerships, events and Park announcements, discover how our occupiers are advancing innovation and shaping the future.

Media enquiries: comms@oxfordsp.com

Vivid Dx: an Oxford spinout racing the clock on sepsis

20 Apr 2026

In the fight against sepsis, speed is everything. Every hour without the right diagnosis increases the risk of death, yet in hospitals around the world, clinicians are still forced to wait days for answers. That stark reality is what drives Vivid Dx, a diagnostics company based at The Oxford Science Park that is transforming how bloodstream infections are detected and treated. The company is built on world-class University of Oxford research,... Read more

Wireless innovator CableFree celebrates 30 years at The Oxford Science Park

31 Mar 2026

CableFree marked a major milestone recently as it celebrated its 30th anniversary. Since its founding in 1996, CableFree has been based at The Oxford Science Park, where it has grown from a small team of visionary engineers into a global provider of 4G, 5G, microwave, millimetre‑wave and Free Space Optics solutions installed in over 90 countries. Over three decades, the company has powered networks across industries including telecoms,... Read more

Evox Therapeutics enters partnership to evaluate new gene editing technology for Rett Syndrome

27 Feb 2026

Evox Therapeutics, a biotechnology company developing innovative therapies for genetically driven neurodegenerative diseases using a next-generation gene editing modality, has announced it is initiating a collaboration with the Rett Syndrome Research Trust (RSRT) to assess the feasibility of using the company’s ExoEdit® exosome-based delivery platform to enable the development of a gene editing treatment for Rett syndrome. Rett syndrome is a... Read more

Boehringer Ingelheim licenses novel oral therapeutics program from Sitryx Therapeutics

27 Feb 2026

Boehringer has acquired an exclusive license for a preclinical, small molecule program from Sitryx, a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory diseases, based at The Oxford Science Park. The deal includes upfront and milestone payments to Sitryx totaling over US $500 million, plus tiered royalties. The program offers a novel, oral, potentially... Read more

CyanoCapture to build world's first robotic GMP facility for oral peptides with Persist AI

25 Feb 2026

CyanoCapture, the innovator in cyanobacteria-based oral drug delivery, and Persist AI, the leader in AI-driven robotic pharmaceutical formulation, have announced a strategic collaboration to jointly build a next-generation GMP manufacturing facility in the San Francisco Bay Area. The facility, expected to be operational later this year, will be the first of its kind to combine cyanobacteria culture and processing with robotic automation for... Read more

News